PL2305300T3 - Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi - Google Patents

Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi

Info

Publication number
PL2305300T3
PL2305300T3 PL09794512.5T PL09794512T PL2305300T3 PL 2305300 T3 PL2305300 T3 PL 2305300T3 PL 09794512 T PL09794512 T PL 09794512T PL 2305300 T3 PL2305300 T3 PL 2305300T3
Authority
PL
Poland
Prior art keywords
cancer
prevention
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Application number
PL09794512.5T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Takanori Saito
Takayoshi Ido
Masaki Shimizu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2305300T3 publication Critical patent/PL2305300T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09794512.5T 2008-07-10 2009-07-10 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi PL2305300T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008180057 2008-07-10
JP2009087379 2009-03-31

Publications (1)

Publication Number Publication Date
PL2305300T3 true PL2305300T3 (pl) 2016-09-30

Family

ID=41507178

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09794512.5T PL2305300T3 (pl) 2008-07-10 2009-07-10 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi

Country Status (16)

Country Link
US (2) US10611835B2 (pl)
EP (1) EP2305300B1 (pl)
JP (1) JP5573156B2 (pl)
KR (1) KR101669834B1 (pl)
CN (1) CN102089004B (pl)
AU (1) AU2009270181B2 (pl)
BR (1) BRPI0910509B8 (pl)
CA (1) CA2730201C (pl)
DK (1) DK2305300T3 (pl)
ES (1) ES2575430T3 (pl)
HU (1) HUE028589T2 (pl)
MX (1) MX2011000117A (pl)
PL (1) PL2305300T3 (pl)
PT (1) PT2305300E (pl)
RU (1) RU2533460C2 (pl)
WO (1) WO2010005068A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
AU2016255255B2 (en) * 2015-04-30 2021-07-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP7029401B2 (ja) 2016-02-02 2022-03-03 フレッド ハッチンソン キャンサー リサーチ センター 抗ｒｏｒ１抗体およびその使用
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
EA202192103A1 (ru) 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
CN116514961B (zh) * 2022-08-19 2025-06-20 浙江农林大学 抗犬瘟热病毒犬源单链抗体scFv4-15及其制备方法与应用
WO2026110853A1 (ja) * 2024-11-20 2026-05-28 東レ株式会社 医薬組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2014073A (en) * 1935-09-10 Stovepipe
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999006541A1 (fr) * 1997-07-29 1999-02-11 Sumitomo Electric Industries, Ltd. Anticorps du recepteur des cellules pre-b non humaines
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
US6703360B2 (en) 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
CA2469833C (en) 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
JPWO2005083074A1 (ja) 2004-03-01 2007-11-22 有限会社金沢大学ティ・エル・オー 腫瘍抗原ペプチド
BRPI0509367A (pt) 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
JP2008512984A (ja) 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP2007053501A (ja) 2005-08-16 2007-03-01 Matsushita Electric Ind Co Ltd 管理装置、ｉｐ電話装置、ｉｐ電話システム及び更新方法
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
MX2008015138A (es) * 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
US20100233167A1 (en) 2007-05-10 2010-09-16 Ramesh Bhatt Chain reaction creating oligomers from repeat units of binding molecules
PT2319533T (pt) 2008-07-10 2017-07-20 Toray Industries Agente indutor de imunidade e método para detetar cancro
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
PL2530091T3 (pl) * 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use

Also Published As

Publication number Publication date
WO2010005068A1 (ja) 2010-01-14
EP2305300A4 (en) 2011-11-02
KR20110039423A (ko) 2011-04-18
AU2009270181B2 (en) 2014-05-29
AU2009270181A1 (en) 2010-01-14
JP5573156B2 (ja) 2014-08-20
CN102089004B (zh) 2018-06-01
KR101669834B1 (ko) 2016-10-27
ES2575430T3 (es) 2016-06-28
RU2011104709A (ru) 2012-08-20
JPWO2010005068A1 (ja) 2012-01-05
BRPI0910509B8 (pt) 2021-05-25
CA2730201A1 (en) 2010-01-14
CA2730201C (en) 2019-02-05
US11993650B2 (en) 2024-05-28
RU2533460C2 (ru) 2014-11-20
CN102089004A (zh) 2011-06-08
US20110129478A1 (en) 2011-06-02
US20200247888A1 (en) 2020-08-06
BRPI0910509A2 (pt) 2015-09-29
MX2011000117A (es) 2011-02-25
BRPI0910509B1 (pt) 2021-05-04
EP2305300B1 (en) 2016-04-06
US10611835B2 (en) 2020-04-07
HUE028589T2 (en) 2016-12-28
EP2305300A1 (en) 2011-04-06
DK2305300T3 (en) 2016-06-06
PT2305300E (pt) 2016-06-16

Similar Documents

Publication Publication Date Title
PT2322221E (pt) Composição farmacêutica para tratamento e prevenção de cancro
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2532743T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
PL2532367T3 (pl) Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
IL219073A (en) A drug combination for cancer treatment
PL2740489T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
PT2740793T (pt) Composição de fármacos para o tratamento e/ou a prevenção de cancro
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
SG10201509279QA (en) Compositions and methods for the prevention and treatment of cancer
IL210494A (en) Organic compounds such as smo inhibitors, pharmaceutical preparations containing them and their use in the treatment of cancer
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
PL3067054T3 (pl) Nowe kompozycje i sposoby leczenia nowotworów
ZA201006988B (en) Method and compositions for treatment of cancer
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
HUE064745T2 (hu) Módszerek és készítmények a rák diagnosztizálására és kezelésére
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
IL243294A0 (en) Compounds and compositions for the treatment of cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2377934A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMOR AND ASTHMA
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia